Anish Suri

All filings by Anish Suri on record concern Cue Biopharma, Inc., in the capacity of chief executive. We count 25 filings; the first trade dates from 21 December 2018 and the latest from 25 August 2023.

On the open market, the record shows 2 purchases worth €18k and 6 sales worth €767k. On balance, insiders were net sellers of €749k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 5 share grants and 12 option exercises. 2023 to date brings 1 purchase and no sales.

On 29 August 2023 came the latest disclosure, an open-market purchase for €10k in Cue Biopharma, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.